New drug duo aims to reboot immune system against tough cancers
NCT ID NCT03156114
Summary
This early-stage study tested a combination of two immunotherapy drugs (BI 754111 and BI 754091) in adults with advanced solid tumors, including non-small cell lung cancer. The first goal was to find the safest highest dose. The second goal was to see if this combination could shrink tumors in patients whose cancer had returned after previous immunotherapy. Treatment was given by IV every three weeks for up to one year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BioVirtus Research Site Sp. z o.o.
Józefów, 05-410, Poland
-
Cross Cancer Institute (University of Alberta)
Edmonton, Alberta, T6G 1Z2, Canada
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Hospital General Universitario Gregorio Marañón
Madrid, 28007, Spain
-
Hospital Politècnic La Fe
Valencia, 46026, Spain
-
Hospital Universitari Dexeus
Barcelona, 08028, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, 28050, Spain
-
John Theurer Cancer Center
Hackensack, New Jersey, 07601, United States
-
Oncology Center-Maria Sklodowska-Curie Institute
Warsaw, 02-781, Poland
-
Princess Margaret Cancer Centre
Toronto, Ontario, M5G 1Z9, Canada
-
Sarah Cannon Research Institute
London, W1G 6AD, United Kingdom
-
Stephenson Cancer Center
Oklahoma City, Oklahoma, 73104, United States
-
Tennessee Oncology, PLLC
Nashville, Tennessee, 37203, United States
-
University of Miami
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.